Clinical Trial for Patients Diagnosed with Mild Cognitive Impairment (Mild Neurocognitive Disorder)

We are currently enrolling patients who have been diagnosed with or who believe to be suffering from amnestic Mild Cognitive Impairment (aMCI; also known as Mild Neurocognitive Disorder). MCI is the onset and worsening of cognitive impairments (such as memory, language, thinking, and judgement) beyond those expected based on your age and education, but which are not significant enough to interfere with your daily activities.

This study will be conducted to evaluate if deep repetitive transcranial magnetic stimulation (deep rTMS) is effective in helping patients suffering from aMCI. Deep rTMS using the Brainsway HMCIPCC coil is investigational, which means it is not yet approved by the FDA.

The study is designed to last for a period of 8 weeks in addition to a one year follow-up appointment. Mood and mental status will be closely monitored with psychological scales and assessments throughout the trial duration. Patients will also undergo daily Brain Training exercises.

 

Figure 1. A sketch of the HMCIPCC coil.

 

Inclusion Criteria:*

– Impaired memory with no additional impairment in day-to-day functioning.
– Ages 55-80 years. If older, patients may participate if there are no active medical problems and have a family history of living to age 90 or older.
– Preserved cognitive (mental) and functional abilities.

 

Exclusion Criteria:*

– Diagnosed with another active unsuccessfully treated psychological disorder.
– Taking medications that increase risk of seizure.
– Taking medications that result in cognitive impairment.
– Current suicidal thoughts or history of attempted suicide in the past year.
– Uncontrolled high blood pressure.
– Personal history of epilepsy or family history of epilepsy in first-degree relatives.
– History of head injury or stroke.
– History of Substance Abuse in the past year.
– Presence of any unstable medical condition.

*This is not a complete list of the inclusion/exclusion criteria to be accepted into the study. For additional information regarding this trial or to see if you qualify, please email Dr. Aron Tendler at aron.tendler@gmail.com, or call 561-333-8884.